CAR T-Cell Therapy Emerges as Preferred Second-Line Treatment for Relapsed/Refractory DLBCL

Insights from the 2026 National Comprehensive Cancer Network (NCCN) Hematologic Malignancies Congress highlight a shift towards favoring CAR T-cell therapy as a second-line treatment for patients with primary refractory diffuse large B-cell lymphoma (DLBCL) or those who relapse within a year. This evolving strategy offers a curative-intent path for patients who previously had limited treatment options.